



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

J.B.Chemicals posts healthy performance in Q1

Mumbai, July 29, 2010: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited financial results for the quarter ended June 2010. The highlights of these results are as under:

STANDALONE RESULTS FOR Q1:

(Rs. in crores)

Net Sales	158.87	Up 17.52% over the same quarter last year
PBT	24.68	Up 51.13% over the same quarter last year
PAT	20.69	UP 57.62% over the same quarter last year
EPS (Rs.)(FV Rs. 2)	2.45	UP 57.05% over the same quarter last year

The company achieved growth of 17.52% in net sales on back of good growth in domestic formulations business and exports to Russia/CIS countries. The key brands focus strategy adopted for domestic market has been yielding good results and helping company create future brands. The company continued to bring in efficiencies by tightening supply chain and working capital management, which is reflected in about 20% lower interest cost and about 10% lower material cost during the quarter.

During this month, the company launched DEFINITY®, an Ultrasound Contrast Imaging product in India under an exclusive marketing arrangement with Lantheus Medical Imaging, Inc. USA, a worldwide leader in diagnostic medical imaging products. This is one of the latest products used for improved results in echocardiograms and diagnosis of kidney and liver functions. The launch of this product is a part of the company's plans to grow its niche contrast media products business.

As a part of the strategy for accelerated growth in domestic formulations business, the company plans to increase field force by 650 by the end of this year, and aims to have field force of 2000 by the end of next year. This increased field force is to expand the coverage of both rural and urban markets.

The company targets growth in exports through aggressive marketing campaigns and new product launches.

Biotech Laboratories (Pty.) Ltd., South Africa ('Biotech'), in which the company has made strategic investment, has turned around last year and is now on a growth path. The company's direct supplies to Biotech during the year are slated to register good growth as number of new products has been added to the outsourcing pact the company has with Biotech.

The company has implemented investment programme that includes (a) further modernization and efficiency enhancement of the formulations facility at Kadaiya and Panoli, (b) new R&D activities, which will *inter alia* facilitate filing of new products registration applications in important markets, and (c) increase in field force to strengthen rural marketing initiatives in domestic market as well as increase in marketing activities in Russia & CIS countries. These initiatives are expected to provide new growth opportunities. The total investment in these areas would be around Rs. 40 crores that is being fully financed by internal accruals.

The plans to set up a factory in SEZ at Panoli have been progressing well. Subject to the necessary approvals, the company plans for this proposed factory to be operational by March 2011.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMFs and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.